Results 131 to 140 of about 5,863 (219)

Precision Adjuvant Strategies in Vaccine Development for Substance Use Disorders: Variability and Mechanistic Insights. [PDF]

Pharmaceutics
Bian Y, Ci Q, Luo XM, Zhang C.
europepmc   +1 more source

Design and mechanistic insights into ZMF59/CpG: a complementary adjuvant system boosting immunity and safety in herpes zoster vaccines. [PDF]

J Nanobiotechnology
Bian L, Li D, Zhou J, Li G, Zhao X, Xing L, Xu J, Shi M, Sun B, Guo Y, Jiang C, Chen Y, Kong W, Zhang Y.   +13 more
europepmc   +1 more source

Effect of Different Adjuvants on the Immunogenicity of a Recombinant Herpes Zoster Vaccine in Mice, Rats and Non-Human Primates. [PDF]

Vaccines (Basel)
Liu X, Gong S, Xu J, Wei Y, Chen X, Wu Y, Zhang Z, Ma J, Yang Y, Tan S.   +9 more
europepmc   +1 more source

Vaccine [PDF]

BackgroundHighly pathogenic avian influenza A (HPAI) viruses found in poultry and wild birds occasionally infect humans and can cause serious disease. In 2014, the Advisory Committee on Immunization Practices (ACIP) reviewed data from one licensed ASO3 ...

core  

Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections. [PDF]

Sci Rep
Singh S, Youssef EG, Barbarino A, Hautau H, Nabeela S, Gebremariam T, Alkhazraji S, Ostroff G, Christensen D, Cochrane T, Ibrahim AS.   +10 more
europepmc   +1 more source

Influenza Vaccines: Current Status, Adjuvant Strategies, and Efficacy. [PDF]

Vaccines (Basel)
Mokalla VR, Gundarapu S, Kaushik RS, Rajput M, Tummala H.   +4 more
europepmc   +1 more source

Innovative adjuvant strategies for next-generation pertussis vaccines. [PDF]

Hum Vaccin Immunother
Yu G, Yang W, Ma Y, Zhang N, Tang D, Jin Y, Shi L, Wang M, Liu D, Xue C, Sun B.   +10 more
europepmc   +1 more source

A Yersinia pestis vaccine development to ensure the safety of humankind [PDF]

, 2013
López Lacalle, Gerard, Universitat Autònoma de Barcelona. Facultat de Biociències   +1 more
core  

PIN15 COST EFFECTIVENESS OF MF59 ADJUVANTED INFLUENZA VACCINE IN FRANCE

Value in Health, 2007
Chambers, J, Eijgelshoven, I, Piercy, J, Wait, S   +3 more
openaire   +1 more source

Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59. [PDF]

NPJ Vaccines
Earnest L, Ruiz DF, Edeling MA, Montoya JC, Yap AHY, Wong CY, Holz LE, Gras S, Collett S, Cooney JP, Davidson KC, Grimley SL, Purcell DFJ, Roberts J, Mumford J, Tan CW, Wang LF, Godfrey DI, Frieman M, Hans D, Vincan E, Anderson DE, Subbarao K, Pellegrini M, Mackenzie JM, Rockman S, Heath WR, Torresi J.   +27 more
europepmc   +1 more source